logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Exelixis' Good News. Prohost Comprehensive Essay with Informative Real Stories About Biotech Stocks

Coming Soon at Prohost Biotech We have stories to tell about our picked stocks which we believe could deepen the Prohost Biotech readers’ understanding of our strategy regarding the evaluation of the biotech companies. Our strategy has made it possible...

Read More

January 7, 2020

0

Japan approved Gilead's product Epclusa®. See Also: A collaboration agreement with Yuhan

Gilead Sciences (GILD) has news that begins with an announcement today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Epclusa ®  (sofosbuvir 400mg/velpatasvir 100mg). Epclusa is once-daily treatment for adults with chronic hepatitis C virus (HCV) infection with decompensated cirrhosis...

Read More

January 8, 2019

0

Encouraging Results From Nektar's Product BEMPEG: NKTR-214 In Combination with the Checkpoint Inhibitor Nivolumab

Nektar Therapeutics Nektar Therapeutics ( NKTR ) announced the publication of Phase 1 clinical data for its immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) + nivolumab, in Cancer Discovery -  a journal of the American Association for Cancer Research. Previously published Phase 1 data in Cancer...

Read More

May 22, 2020

0

Why the Recent Data from the Trial of Moderna's mRNA Vaccine is Important and Significant

Moderna's mRNA Vaccine Today could be one of the important early days as Moderna ( MRNA ) succeeded in cementing proof of concept for the validity of its messenger RNA ( mRNA ) as a vaccine. Moderna announced yesterday positive...

Read More

January 10, 2020

0

The XBiotech Interesting News That Rallied Its Stock

XBiotech XBiotech ( XBIT ), headquartered in Austin, Texas, develops innovative proprietary manufacturing technology that reduces the cost and complexity of biological drug production. XBiotech  is dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies. The firm is currently advancing...

Read More

January 14, 2020

0

Nektar Is Still a Favorite

Nektar in the NEWS T he FDA's Anesthetic and Analgesic Advisory Committee ( AADPAC ) and Drug Safety and Risk Management Advisory Committee ( DSaRM ) unanimously voted no regarding the approval of Nektar Pharmaceuticals’ ( NKTR ) New Drug Application (...

Read More

January 15, 2020

0

The FDA committee voted 19 to 1 in favor of approving Amgen's & UCB's new osteoporosis product Evenity

On January 8, 2019 the osteoporosis monoclonal antibody Evenity (romosozumab) developed by Amgen and UCB was granted approval by the Japanese Ministry of Health, Labor and Welfare for osteoporosis in patients at high risk of bone fracture. Yesterday , Amgen (AMGN)   and...

Read More

January 17, 2019

0

Midday January 16, 2020 Outperforming Prohost Picks

Outperforming Prohost Picks  January 16, 2020 at 11:30 am EST MRNA Trading at $21.35 UP $1.01 AMGN Trading at $243.50 UP $1.80 FTSV  Trading at $40.00 UP $3.20 RETA Trading at $217.01 UP $4.56 ALNY Trading at $119.26 UP $1.17...

Read More

January 16, 2020

0

Why Sonoma Pharmaceuticals and Adaptimmune Stock Prices Skyrocketed

Sonoma Pharmaceuticals and MicroSafe Group, Dubai Sonoma Pharmaceuticals ( SNOA ) develops stabilized hypochlorous acid (HOCl) products for a wide range of applications including: wound care, eye care and dermatological conditions. Together with MicroSafe Group, Dubai, announced the receipt of...

Read More

May 29, 2020

0

Lipocine's product, LPCN-1144, has promising results in decreasing the risk of NASH in non-alcoholic fatty liver disease

Lipocine (LPCN) , a specialty pharmaceutical company, announced that an approximately eight-week top-line study using LPCN 1144 in subjects with non- alcoholic fatty liver disease (NAFLD) who might have the potential to develop NASH.  Treatment results showed an absolute mean...

Read More

January 17, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 89
  • 90
  • 91
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy